Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Gilteritinib Remains Clinically Active in Relapsed/Refractory FLT3 Mutated AML Previously Treated with FLT3 inhibitors

Yazan Numan, MD, Zaid Abdel Rahman, MD, Justin Grenet, MD, Stephanie Boisclair, MD, Jan Philipp Bewersdorf, MD, Dylan Barth, PharmD, BCPS, Amer M. Zeidan, MBBS, MHS, Musa Yilmaz, MD, Shira Dinner, MD, Yehuda E. Deutsch, MD, Olga Frankfurt, MD, Mark Litzow, MD, Aref Al-Kali, MD, James M. Foran, MD, Lisa Z. Sproat, MD, Borko Jovanovic, PhD, Naval Daver, MD, Alexander E. Perl, MD, Jessica K. Altman, MD

Blood (2020) 136 (Supplement 1): 5–7.

https://doi.org/10.1182/blood-2020-137251

Published: 2020

Journal Articles

A Phase I-II Trial of DA-EPOCH-R Plus Ixazomib As Frontline Therapy for Patients with MYC-Aberrant Lymphoid Malignancies: The Daciphor Regimen

Carlos Galvez, MD, Reem Karmali, MDMSc, Mehdi Hamadani, MD, Leo I. Gordon, MD, Jane N. Winter, MD, Shuo Ma, MD PhD, Valerie Nelson, MD MBA, Brett Alan Palmer, BS, Timothy S. Fenske, MD, Nirav N. Shah, MD, Deepa Jagadeesh, MDMPH, Andreas Klein, MD, Irene Helenowski, PhD, Borko Jovanovic, PhD, Adam M Petrich, MD, Andrew M. Evens, DO,MMSc, Barbara Pro, MD

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-138532

Published: 2020

Journal Articles

A Phase I/II Trial of Brentuximab Vedotin (BV) Plus Rituximab (R) As Frontline Therapy for Patients with Immunosuppression-Associated CD30+ and/or EBV+ Lymphomas

William Pearse, MD, Barbara Pro, MD, Leo I. Gordon, MD, Reem Karmali, MD, Jane N. Winter, MD, Shuo Ma, MD PhD, Amir Behdad, MD, Andreas Klein, MD, Adam M. Petrich, MD, Borko Jovanovic, PhD, Sonali M. Smith, MD, Andrew G Evans, MD PhD

Blood (2019) 134 (Supplement_1): 351.

https://doi.org/10.1182/blood-2019-127390

Published: 2019

Journal Articles

Sequential Brentuximab Vedotin (Bv) before and after Adriamycin, Vinblastine, and Dacarbazine (Bv-AVD) for Older Patients with Untreated Classical Hodgkin Lymphoma (cHL): Final Results from a Multicenter Phase II Study

Andrew M Evens, DO,MSc, Ranjana H. Advani, MD, Michelle A. Fanale, MD, Sonali M. Smith, MD, Irene Helenowski, PhD, Borko Jovanovic, PhD, R. Gregory Bociek, MD, Andreas Klein, MD, Jane N. Winter, MD, Leo I. Gordon, MD, Paul A. Hamlin, MD

Blood (2017) 130 (Supplement 1): 733.

https://doi.org/10.1182/blood.V130.Suppl_1.733.733

Published: 2017

Journal Articles

A Multicenter Phase II Clinical Trial of Rituximab Combined with Bortezomib (VELCADE®) Therapy for Untreated “High Tumor Burden” Indolent Non-Hodgkin Lymphoma (NHL)

Andrew M. Evens, DO, MSc, Mitchell R Smith, MD, PhD, Izidore S Lossos, MD, Borko Jovanovic, PhD, Adam Cohen, MD, Jane N. Winter, MD, Steven T. Rosen, MD, FRCPA, Leo I. Gordon, MD

Blood (2012) 120 (21): 1642.

https://doi.org/10.1182/blood.V120.21.1642.1642

Published: 2012

Journal Articles

A Phase 2 Clinical Trial Adding Rituximab to CODOX-M/IVAC for Untreated Burkitts Lymphoma: Correlative Analysis of Serum and CSF Rituximab Levels

Andrew M. Evens, DO, MSc, Nahida Islam, MD, Kenneth R. Carson, MD, Victoria Browning, PhD, Chadi Nabhan, MD, FACP, Borko Jovanovic, PhD, Paul M. Barr, MD, Paolo F. Caimi, MD, Irene Helenowski, PhD, Stephanie A. Gregory, Jill Kolesar, PhD, Leo I. Gordon, MD

Blood (2012) 120 (21): 1640.

https://doi.org/10.1182/blood.V120.21.1640.1640

Published: 2012

Journal Articles

Integration of Rituximab and Liposomal Doxorubicin (DOXIL®) Into CODOX-M/IVAC for HIV-Negative and HIV+ Adults with Untreated Burkitt's Lymphoma (BL): Results of a Prospective Multicenter Phase II Study

Andrew M. Evens, DO, MSc, Kenneth R. Carson, MD, Chadi Nabhan, MD, FACP, Borko Jovanovic, PhD, Paul Barr, MD, Lilia Gallot, Irene Helenowski, MS, Paolo F. Caimi, MD, Stephanie A. Gregory, MD, Leo I. Gordon, MD, FACP

Blood (2011) 118 (21): 2669.

https://doi.org/10.1182/blood.V118.21.2669.2669

Published: 2011

Journal Articles

Busulfan, Cyclophosphamide, and Etoposide (Bu/Cy/VP-16) Is An Effective Conditioning Regimen Prior to Allogeneic or Autologous Stem Cell Transplantation for Primary Refractory or Relapsed Non-Hodgkin’s Lymphoma

Neelima Vidula, MD, Borko Jovanovic, PhD, Jane N. Winter, MD, Jayesh Mehta, MD, Seema Singhal, MD, Stephanie F. Williams, MD, Olga Frankfurt, MD, Jessica K. Altman, MD, Joanne Monreal, AAS, Andrew M. Evens, DO, MSc, Leo I. Gordon, MD, FACP

Blood (2011) 118 (21): 4499.

https://doi.org/10.1182/blood.V118.21.4499.4499

Published: 2011

Journal Articles

A Phase I/II Trial of Radioimmunotherapy (RIT) with 90 Yttrium-Ibritumomab Tiuxetan (Zevalin®; 90 Y-Zevalin) Combined with the Redox-Active Agent Motexafin Gadolinium (MGd): Prompt and High Remission Rates in Patients with Rituximab-Refractory Non-Hodgkin’s Lymphoma (NHL).

Andrew M. Evens, DO, MS, Stewart Spies, MD, David Patton, MS, Irene Helenowski, MS, Borko Jovanovic, PhD, Sarah Miyata, RN, ACNP, Elizabeth Hamilton, RN, CNP, M. Wayne Saville, MD, Richard A. Miller, MD, Jane N. Winter, MD, Leo I. Gordon, MD

Blood (2007) 110 (11): 2558.

https://doi.org/10.1182/blood.V110.11.2558.2558

Published: 2007

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Gilteritinib Remains Clinically Active in Relapsed/Refractory FLT3 Mutated AML Previously Treated with FLT3 inhibitors

A Phase I-II Trial of DA-EPOCH-R Plus Ixazomib As Frontline Therapy for Patients with MYC-Aberrant Lymphoid Malignancies: The Daciphor Regimen

A Phase I/II Trial of Brentuximab Vedotin (BV) Plus Rituximab (R) As Frontline Therapy for Patients with Immunosuppression-Associated CD30+ and/or EBV+ Lymphomas

Sequential Brentuximab Vedotin (Bv) before and after Adriamycin, Vinblastine, and Dacarbazine (Bv-AVD) for Older Patients with Untreated Classical Hodgkin Lymphoma (cHL): Final Results from a Multicenter Phase II Study

A Multicenter Phase II Clinical Trial of Rituximab Combined with Bortezomib (VELCADE®) Therapy for Untreated “High Tumor Burden” Indolent Non-Hodgkin Lymphoma (NHL)

A Phase 2 Clinical Trial Adding Rituximab to CODOX-M/IVAC for Untreated Burkitts Lymphoma: Correlative Analysis of Serum and CSF Rituximab Levels

Integration of Rituximab and Liposomal Doxorubicin (DOXIL®) Into CODOX-M/IVAC for HIV-Negative and HIV+ Adults with Untreated Burkitt's Lymphoma (BL): Results of a Prospective Multicenter Phase II Study

Busulfan, Cyclophosphamide, and Etoposide (Bu/Cy/VP-16) Is An Effective Conditioning Regimen Prior to Allogeneic or Autologous Stem Cell Transplantation for Primary Refractory or Relapsed Non-Hodgkin’s Lymphoma

A Phase I/II Trial of Radioimmunotherapy (RIT) with 90 Yttrium-Ibritumomab Tiuxetan (Zevalin®; 90 Y-Zevalin) Combined with the Redox-Active Agent Motexafin Gadolinium (MGd): Prompt and High Remission Rates in Patients with Rituximab-Refractory Non-Hodgkin’s Lymphoma (NHL).

Email alerts

ASH Publications

American Society of Hematology